Luca Issi: Got it. Thanks so much.
Operator: Our next question comes from Steve Seedhouse with Raymond James. Please proceed with your question.
Timur Ivannikov: Hi. Good morning. This is Timur Ivannikov, on for Steve Seedhouse. So we just had a clarification question on your PRO tools in RUBY. To what extent are you going to be using the same tools that Vertex and CRISPR used before like [EQ, VAS, FACT-G, BMT]? And to what extent do you think of including new tools? And on the issue being you’re not going to be able to do a clean cross-trial comparison potentially here? Thank you.
Baisong Mei: Yes. Thank you for the question. As I mentioned, comment earlier, we use the tool from two ends. One is more general, the quality of life tool as well as the sickle cell specific. And as you mentioned, the specific of the tool we’re using, that’s the problem for – evaluate the fatigue of the patient, which is important not complain from the sickle cell patient. Just give example wise. And you are very much of – that exactly the direction we were thinking, trying to see, okay, what are the specific instruments be able to detect that major complaint from the sickle cell patient such as fatigue, such as pain, among other things.
Gilmore O’Neill: Yes. So we are actually using a number of instruments. Some were used by Vertex and we have additional instruments in our PRO and armamentarium and they are actually being collected in the RUBY Phase 1, 2, 3 trial as we speak.
Operator: Our next question comes from Jack Allen with Baird. Please proceed with your question.
Jack Allen: Great. Thanks so much for taking the question and congratulations on the progress. I want to touch a little bit on the patient experience with reni-cel. Have you provided any disclosures around the number of apheresis cycles that are required to receive reni-cel and I was wondering if the higher editing efficiency of AsCas12a shorter amount of apheresis cycles. And then on the back end after treatment, what are you seeing as it relates to time to neutrophil engraftment? And how do you think that compares to some of the competing products in the space? Thanks so much.
Gilmore O’Neill: Thanks very much, Jack. I’m actually going to ask Baisong to talk about the clinical experience with apheresis and other elements of the patient experience and honestly touch on neutrophil engraftment with which we have been very pleased to-date?
Baisong Mei: Thank you, Jack. For patient experience, I mean, apheresis is a very important part of that. As I mentioned earlier, since I joined, I work with a team and an expert, we amended the protocol and trying, to optimize the apheresis process. So now, we are very happy with the number of cycles that patient has been going through and we can see that’s already improvement from what we had before. In terms of the engraftment, as we disclosed that in ASH, we have all the patients have engraftment within 30 days. So we’re very happy about that, and we continue to see the similar data as we follow through the protocol for our studies.
Jack Allen: Great. Thanks a lot for the color.
Baisong Mei: Thank you very much.
Operator: We have reached the end of our question-and-answer session. This concludes today’s conference. Thank you for your participation. You may disconnect your lines at this time.
